Weaning critically ill children undergoing prolonged sedation: challenges in achieving standardized practice
- 1Department of Emergency and Critical Care, Anesthesia and Pediatric Intensive Care Unit, Meyer Children’s Hospital, IRCCS, Florence, Italy
- 2Department of Health Science, Section of Anesthesia and Intensive Care, University of Florence, Piazza di San Marco 4, Florence, Italy
Abstract
Introduction: The aim of this study was to observe how drug dose reduction and interruption is conducted in critically ill children receiving sedation for longer than 5 days, analyzed as drug dose percentage modifications relative to the first day of weaning. We also assessed adherence to a predefined tapering target between 10 and 20% of the initial sedative dose.
Methods: Retrospective cohort study in a tertiary pediatric intensive care unit (PICU).
Results: Overall, 41 patients were enrolled. The cohort median (interquartile range) daily percentage reductions during the weaning phase were 10.6% (3.8–20.4) for fentanyl, 3.3% (0–13.7) for midazolam, 0% (0–10.7) for dexmedetomidine, 5.4% (0–15.4) for ketamine, and 10.5% (0–20.0) for propofol. Median reductions were significantly lower from the 20% target for midazolam, dexmedetomidine, ketamine, and propofol, while fentanyl showed a borderline difference. Adherence to the scheduled tapering range (10–20%) was low across all sedatives during weaning phase. Fentanyl had the highest proportion of weaning days within the target range (19.8%). Overall, only 16 (39%) patients had Withdrawal Assessment Tool 1 (WAT-1) data. Of these, 8 (50%) were positive on the first day of evaluation and three (18%) on the last day.
Conclusion: In children sedated for more than 5 days the recommended weaning rate was rarely respected. Withdrawal monitoring was suboptimal and did not guide drug weaning.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12887-026-07545-4.
Related
- Tazemetostat combined PD-1 inhibitor achieving prolonged survival in primary proximal epithelioid sarcoma: a case report and review of the literature.
- Cefepime exposure in prolonged or intermittent infusion in critically ill children
- Opportunities and Challenges to Achieving the Australian Cancer Plan Goal of World Class Health Systems for Optimal Cancer Care
- A nurse-led standardized bedside gastric ultrasound monitoring protocol for abdominal distension management in critically ill patients receiving enteral nutrition: a pragmatic, exploratory randomized controlled trial.
- Exploratory clinical predictors of prolonged hospital stay in patients with patent foramen ovale undergoing transthoracic echocardiography- or X-ray-guided closure
BibTeX
@article{colosimo2026weaning,
title = {{Weaning critically ill children undergoing prolonged sedation: challenges in achieving standardized practice}},
author = {Denise Colosimo and Diletta Bindi and Diletta Mannini and Edoardo Piombino and Zaccaria Ricci},
journal = {BMC Pediatrics},
year = {2026},
month = aug,
doi = {10.1186/s12887-026-07545-4},
url = {https://doi.org/10.1186/s12887-026-07545-4},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Weaning critically ill children undergoing prolonged sedation: challenges in achieving standardized practice
AU - Denise Colosimo
AU - Diletta Bindi
AU - Diletta Mannini
AU - Edoardo Piombino
AU - Zaccaria Ricci
PY - 2026
DA - 2026/08/15
JO - BMC Pediatrics
DO - 10.1186/s12887-026-07545-4
UR - https://doi.org/10.1186/s12887-026-07545-4
AB - Introduction: The aim of this study was to observe how drug dose reduction and interruption is conducted in critically ill children receiving sedation for longer than 5 days, analyzed as drug dose percentage modifications relative to the first day of weaning. We also assessed adherence to a predefined tapering target between 10 and 20% of the initial sedative dose. Methods: Retrospective cohort study in a tertiary pediatric intensive care unit (PICU). Results: Overall, 41 patients were enrolled. The cohort median (interquartile range) daily percentage reductions during the weaning phase were 10.6% (3.8–20.4) for fentanyl, 3.3% (0–13.7) for midazolam, 0% (0–10.7) for dexmedetomidine, 5.4% (0–15.4) for ketamine, and 10.5% (0–20.0) for propofol. Median reductions were significantly lower from the 20% target for midazolam, dexmedetomidine, ketamine, and propofol, while fentanyl showed a borderline difference. Adherence to the scheduled tapering range (10–20%) was low across all sedatives during weaning phase. Fentanyl had the highest proportion of weaning days within the target range (19.8%). Overall, only 16 (39%) patients had Withdrawal Assessment Tool 1 (WAT-1) data. Of these, 8 (50%) were positive on the first day of evaluation and three (18%) on the last day. Conclusion: In children sedated for more than 5 days the recommended weaning rate was rarely respected. Withdrawal monitoring was suboptimal and did not guide drug weaning. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12887-026-07545-4.
SN - 1471-2431
ER -